BofA Securities analyst Tazeen Ahmad maintains $Incyte (INCY.US)$ with a buy rating, and maintains the target price at $86.
According to TipRanks data, the analyst has a success rate of 50.5% and a total average return of 3.2% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Incyte (INCY.US)$'s main analysts recently are as follows:
Following the announcement that Incyte will halt enrollment in their Phase 2 trial for INCB000262 in chronic spontaneous urticaria due to findings from a preclinical in vivo study, it has been noted that these assets were mainly in a proof-of-concept stage and were not considered a major driver of pipeline value. For now, it is assumed that this molecule is discontinued, hence, an adjustment in the modeled pipeline value has been made, reducing it from previous estimates.
The firm's decision on their outlook for Incyte was influenced by the announced and considered disappointing enrollment pause for MRGPRX2 due to preclinical toxicity findings. Despite the high-risk nature of this early asset, its potential was noted in the substantial market opportunities in CSU/CInDU. This program was regarded as one of Incyte's more significant projects with transformative potential if successful. Current uncertainties on the future steps and data readout timelines for this program are pending further clarity from regulatory authorities.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美銀證券分析師Tazeen Ahmad維持$因塞特 (INCY.US)$買入評級，維持目標價86美元。
根據TipRanks數據顯示，該分析師近一年總勝率為50.5%，總平均回報率為3.2%。
此外，綜合報道，$因塞特 (INCY.US)$近期主要分析師觀點如下：
根據因塞特宣佈，由於臨床前體內研究發現，INCB000262用於慢性特發性蕁麻疹的2期試驗中止招募，注意到這些資產主要處於概念階段，不被視爲管線價值的主要推動因素。目前，可以假定這種分子已經停止使用，因此，在建模管線價值上做出了調整，從之前的估計中降低了價值。
該公司對因塞特前景的決定受到了MRGPRX2臨床前毒性發現導致的招募暫停的影響，這種早期資產存在較高的風險，但在慢性特發性蕁麻疹/慢性耐藥性蕁麻疹的巨大市場機會中具有潛力。如果成功，該項目將被視爲因塞特更重要的具有轉型潛力的項目之一。對該項目未來步驟和數據發佈時間表的當前不確定性等待進一步來自監管機構的澄清。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
